AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00679939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: up to 2000mg/day
Study NCT00688818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
Study NCT00688818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
Study NCT03292250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Study NCT03292250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Study NCT03292250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Initial dose 200 mg twice per day orally according to study protocol.
Study NCT03292250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Study NCT03292250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab,Tremelimumab
Description: Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Study NCT01284348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept 15 mg
Description: Sotatercept 15 mg SC injection once every 42 days, up to four doses
Study NCT01284348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept 30 mg
Description: Sotatercept 30 mg SC injection once every 42 days, up to four doses
Study NCT02991781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback and Neurofeedback Training
Description: The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
Study NCT04559100 — intervention group
Intervention type: RADIATION
Intervention: chest radiography
Description: 6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
Study NCT03389230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2(EQ)BBζ/CD19t+ T cells
Description: Given via catheter
Study NCT03389230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03389230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT04559100 — intervention group
Intervention type: RADIATION
Intervention: thoracic computed tomography scan
Description: 6 and 12 months after hospital discharge, if the patient had a CT scan upon admission to the hospital. If the study is normal at 6 months it will not be repeated at 12 months.
Study NCT04559100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: 6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
Study NCT04559100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusing capacity of carbon monoxide
Description: 6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
Study NCT04559100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minute walk test
Description: 6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
Study NCT04559100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: saint george respiratory questionnaire
Description: 6 and 12 months after hospital discharge.
Study NCT02209519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole (male partner)
Description: 500 mg PO BID for 7 days
Study NCT02209519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placeob (male partner)
Description: matching placebo capsules PO BID for 7 days
Study NCT02329379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Study NCT02329379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Study NCT02991781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline use for smoking cessation
Description: The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
Study NCT02631122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular vs Retroclavicular Nerve Block
Description: An ultrasound-guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% ropivicaine will be performed on patients scheduled for lower arm surgery; 25 ml to be delivered to the brachial plexus and 5 ml to the intercostal nerve
Study NCT02170974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS polymorph II
Study NCT02170974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS polymorph I
Study NCT00693238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Risk Proton Radiation
Study NCT00693238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intermediate Risk Proton Radiation
Study NCT02991781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Neurofeedback
Description: Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
Study NCT02991781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Control
Description: Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
Study NCT04520750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita
Study NCT00174499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Description: 2 mg nicotine gum
Study NCT00174499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Description: 4 mg nicotine gum
Study NCT02733237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (40 IU)
Study NCT02733237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo (40 IU)
Study NCT03104205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluate home-based MOWI
Description: MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
Study NCT03649737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Attend supervised and unsupervised exercise sessions
Study NCT03649737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03296644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II correction using PowerScope2
Study NCT03296644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II correction using Forsus
Study NCT03649737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01806974 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oral exam and
Description: The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
Study NCT00197756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin A alone
Description: 30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
Study NCT02660567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amr maneuver
Description: sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
Study NCT02642120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental device Laboraide
Description: After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire.
Study NCT00827905 — intervention group
Intervention type: DEVICE
Intervention: RSpot Non-Contact Respiratory Rate Spot Check
Description: The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
Study NCT01941849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
Study NCT01941849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-mIBG
Description: Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
Study NCT02254590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigation Endoscopic Decompressive Laminotomy
Description: 2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
Study NCT03555318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory visit
Description: All patients will have an ambulatory visit with the cardiologist.
Study NCT03555318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined ambulatory visit
Description: Both the geriatrician and cardiologist will evaluate the patient and cardiac treatment will be agreed on between both specialists.
Study NCT03555318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric intervention
Description: After the geriatric assessment, measures to improve frailty will be started.
Study NCT03998384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrobulbar injection of autoserum
Description: Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
Study NCT00197756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Multivitamins excluding vitamin A
Description: 30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
Study NCT00197756 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: multivitamins including vitamin A
Description: 20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
Study NCT03998384 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: retrobulbar injection of placebo
Description: Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
Study NCT04463251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104 80 mg
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
Study NCT04463251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
Study NCT04463251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
Study NCT04490512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluBHPVE6E7
Description: Multiple subcutaneous, intradermal or intramuscular administrations
Study NCT04490512 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: FluBHPVE6E7
Description: Multiple subcutaneous, intradermal or intramuscular administrations
Study NCT03505684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CTP
Description: 1,000 mg of CTP was orally administered per day for 12 weeks.
Study NCT03505684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (starch)
Description: placebo (starch)
Study NCT00827216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
Study NCT00197756 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: Placebo pill taken orally once per day during pregnancy and lactation
Study NCT00827216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
Study NCT00687843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-gimeracil-oteracil potassium (TS-1)
Description: 80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
Study NCT00687843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium (TS-1)
Description: 80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
Study NCT00687843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin (PSK)
Description: 3 g, PO from day 1 to day 336
Study NCT01829100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Behavioral Activation Therapy (GBAT)
Description: GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
Study NCT02550756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTNX-4975
Study NCT02537132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptation and training to Non Invasive Ventilation (NIV)
Description: Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
Study NCT02537132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adaptation and training to Non Invasive Ventilation (NIV)
Description: Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
Study NCT01722825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally.
Study NCT03324386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Individual Orientation
Description: This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.
Study NCT03324386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: VLE for Distance Learning
Description: Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
Study NCT03324386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: E-blended Lerarning
Description: This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
Study NCT03324386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy - Control Group
Description: This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,
Study NCT01024140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.